Immuno-Oncology

Jeffrey S. Weber, MD, PhD, discusses the future of immunotherapy in the treatment of melanoma.

Joshua Bauml, MD, assistant professor, Perelman School of Medicine, University of Pennsylvania, discusses the role of liquid biopsies for patients with lung cancer.

Arun S. Singh, MD, Ronald Reagan UCLA Medical Center, discusses the rationale behind a randomized phase II study (NCT02880020) of nivolumab (Opdivo) monotherapy versus nivolumab with ipilimumab (Yervoy) in patients with metastatic or unresectable gastrointestinal stromal tumors (GIST).

Although there has been reluctance among oncology researchers to administer immunotherapy to patients with HIV who develop cancer, early signals from a small clinical trial suggest that such a strategy may be safe in certain settings.

Development of effective therapies for metastatic head and neck cancer has been challenging, and progress has been slow.

Rana R. McKay, MD, medical oncologist, assistant professor, Moores Cancer Center at the University of California, San Diego, discusses combinations in renal cell carcinoma.

Combining the investigational oral cancer stem cell pathway inhibitor napabucasin with the PD-1 inhibitor pembrolizumab showed a signal of efficacy in the first 8 patients enrolled in a multicenter phase I/II trial of patients with metastatic colorectal cancer.

Andrew L. Pecora, MD, president of the Physician Services Division and chief innovation officer at Hackensack Meridian Health, discusses the results of a trial investigating the combination of CTLA-4 and PD-1 inhibitors for patients with multiple myeloma.

Edward B. Garon, MD, director of Thoracic Oncology at the Jonsson Comprehensive Cancer Center at UCLA, discusses sequencing challenges for patients with advanced lung cancer.

ASP0113, an investigational DNA vaccine developed for cytomegalovirus-seropositive hematopoietic stem cell transplant patients, has failed to meet its primary and secondary endpoints.